IBS Clinical Trial
Official title:
A New Dimension in Modeling Irritable Bowel Syndrome (IBS) to Elucidate Novel Diagnostic Biomarkers and Microbiome Signatures
Microbiota from fecal samples from IBS-D patients, in combination with vitamin D supplementation added to our 3-D immunocompetent intestinal models will establish a high fidelity disease model to achieve our long-term goal to understand the relationship between gut microbiome, vitamin D levels, host gene expression and IBS-D symptoms that could ultimately be used as a testing platform for treatment and prevention.
The pathophysiology of IBS is not well understood. Preliminary studies support IBS-D patients with varied microbiome fingerprints, vitamin D levels, and blood serotonin levels compared to non-IBS patients. The investigators have novel 3-D immunocompetent intestinal models to establish a new model of high fidelity disease to examine the relationship of IBS-D patients gut microbiome, with supplemental vitamin D levels, and the relationship of blood serotonin and vitamin D levels. IBS-D patients and healthy controls will be asked to provide a fecal sample, a biopsy sample of colonic tissue obtained during a clinically appropriate flexible sigmoidoscopy or colonoscopy, and a blood sample. There will be 1-2 office visits. One visit will last 30 minutes, the second visit no longer than 3 hours. This study is funded by a combined MAYO-Arizona State University seed grant. The samples will be analyzed at ASU. Our long-term goal is to understand the relationship between gut microbiome, vitamin D levels, host gene expression, serotonin levels, and IBS-D symptoms that could ultimately be used as a testing platform for treatment and prevention of this highly prevalent disorder. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04677881 -
Health Effects of Different Types of Bread
|
N/A | |
| Completed |
NCT02293343 -
24 Hrs Histamine Profile in Healthy Persons and Patients With Food Intolerance
|
N/A | |
| Completed |
NCT01717404 -
Effects of Mexiletine on Colonic Transit in a Patient With Irritable Bowel Syndrome - Constipation (IBS-C)
|
Phase 1 | |
| Withdrawn |
NCT02313207 -
Confocal Laser Endomicroscopy in IBS Patients
|
N/A | |
| Completed |
NCT02937506 -
Patient Satisfaction With Propofol for Out Patient Colonoscopy
|
Phase 4 | |
| Terminated |
NCT05579444 -
Systems Biology of Gastrointestinal and Related Diseases
|
||
| Recruiting |
NCT06389851 -
Effects of Tomato Consumption on Steatosis, Intestinal Function and Glucose and Lipid Metabolism in Subjects With NAFLD
|
N/A | |
| Recruiting |
NCT05815602 -
Ebastine Versus Mebeverine in IBS Patients
|
Phase 3 | |
| Completed |
NCT03482765 -
A Study of Probiotics in IBS Subjects
|
N/A | |
| Completed |
NCT03986476 -
The Effect of Two Probiotic Products on the Intestinal Barrier Function in Patients With Irritable Bowel Syndrome
|
N/A | |
| Recruiting |
NCT06275906 -
Influence of a Mediterranean Diet Combined With a Physical Activity Intervention, on NAFLD and Inflammation Parameters.
|
N/A | |
| Not yet recruiting |
NCT05737277 -
Gabapral in Pediatric IBS
|
N/A | |
| Active, not recruiting |
NCT05718505 -
Comparison of the Atmo Motility Gas Capsule System to the Reference Standard
|
N/A | |
| Recruiting |
NCT06072287 -
The Living With a Long-Term Condition Study
|
||
| Completed |
NCT04953728 -
Optimization of Transcutaneous Electrical Acustimulation (TEA) Modalities for Treatment of IBS-C
|
N/A | |
| Completed |
NCT02681666 -
Mindfulness-Based Eating in Patients With Irritable Bowel Syndrome
|
N/A | |
| Completed |
NCT02981888 -
Fecal Metabolome and the Intestinal Microbiota in Irritable Bowel Syndrome
|
||
| Completed |
NCT01667627 -
Probiotic in Irritable Bowel Syndrome (IBS) Patients With Diarrhea
|
Phase 4 | |
| Recruiting |
NCT01779765 -
The Efficacy of Hydrolyzed Guar Gum ( PHGG) in the Treatment of Patients With Irritable Bowel Syndrome (IBS)
|
Phase 4 | |
| Completed |
NCT02009618 -
The Effects of Rifaximin Therapy in Irritable Bowel Syndrome
|
N/A |